NCT07487454Not yet recruiting
Sham-Controlled Rapid-Acting Neuromodulation for Depression
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults. The main questions it aims to answer are: * Does accelerated iTBS reduce depressive symptoms compared to sham (placebo) stimulation? * Are there measurable brain, biological, and digitally measured emotion changes associated with treatment response? Participants will: * Be randomly assigned to receive either active iTBS or sham stimulation * Receive 10 stimulation sessions per day for 5 consecutive days (total of 50 sessions) * Complete MRI brain scans and EEG recordings before and after treatment * Provide blood and saliva samples to measure biological markers * Complete depression rating scales and questionnaires at baseline, during treatment, and at follow-up visits * Use a secure mobile app to record brief facial and vocal samples during the 5-day treatment and at follow-up visits * Return for follow-up visits at 1 week and at 1, 3, 6, and 12 months after treatment
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 264 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- University of California, Davis
- Diseases
- Depression
- NCT number
- NCT07487454
What you commit to
- Study type: Interventional
- Planned participants: 264
- From 1 Dec 2026 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion
- Contraindications to receiving TMS and/or MRI as determined by screening questionnaires
- Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies.
Other illness
- Unable to consent (due to medical condition, acute psychosis, substance use, etc)
Other
- Active substance use or severe substance use that in the opinion of the PI would interfere with study participation
- Untreated, active psychosis
- Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study
Who the study is looking for
- English speaking
- Able to provide informed consent
- 18-65 years old
- Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UC Davis Medical Center Coordinator of this site? Confirm its status | Sacramento | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.